Patents Assigned to SILLAJEN, INC.
  • Immune Assay for Monitoring Response to Oncolytic Vaccinia Virus and Uses Thereof
    Publication number: 20220381769
    Abstract: Provided herein are methods and compositions for assaying vaccinia virus-specific T cell responses in a sample from a subject undergoing treatment with an oncolytic vaccinia virus. The compositions comprise custom peptide pools from known immunogenic vaccinia virus epitopes in an HLA-agnostic format to profile peripheral CD8+T cell responses.
    Type: Application
    Filed: September 23, 2020
    Publication date: December 1, 2022
    Applicants: SillaJen, Inc., Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas GASPAR, Raquel DEERING, Myles DILLON
  • Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
    Patent number: 10646524
    Abstract: The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 12, 2020
    Assignee: SILLAJEN, INC.
    Inventors: Tae Ho Hwang, Nam Hee Lee, Euna Cho
  • ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY
    Publication number: 20200085891
    Abstract: A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer.
    Type: Application
    Filed: April 23, 2018
    Publication date: March 19, 2020
    Applicant: SillaJen, Inc
    Inventors: Chan KIM, Hongjae JEON, Eun Sang MOON, Sungkuon CHI, Jiwon Sarah CHOI, Joon-goo JUNG, Jungu BAE
  • Compositions and methods for viral embolization
    Patent number: 10517910
    Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 31, 2019
    Assignee: SILLAJEN, INC.
    Inventors: Tae Ho Hwang, Nam Hee Lee, Mong Cho, Ungbae Jeon, Doo Jin Byun
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 10434169
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 8, 2019
    Assignees: SILLAJEN, INC, SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • COMPOSITIONS AND METHODS FOR VIRAL EMBOLIZATION
    Publication number: 20180303886
    Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
    Type: Application
    Filed: June 17, 2016
    Publication date: October 25, 2018
    Applicant: SillaJen, Inc.
    Inventors: Tae Ho HWANG, Nam Hee LEE, Mong CHO, Ungbae JEON, Doo Jin BYUN
  • MODIFIED ONCOLYTIC VACCINIA VIRUSES EXPRESSING A CYTOKINE AND A CAR- BOXYLESTERASE AND METHODS OF USE THEREOF
    Publication number: 20180271921
    Abstract: The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.
    Type: Application
    Filed: September 2, 2016
    Publication date: September 27, 2018
    Applicant: SillaJen, Inc.
    Inventors: Tae Ho HWANG, Nam Hee LEE, Euna CHO
  • GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
    Publication number: 20180214538
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 2, 2018
    Applicants: SILLAJEN BIOTHERAPEUTICS, INC., SILLAJEN, INC.
    Inventors: David KIRN, John BELL, Caroline BREITBACH, Anne MOON, Tae-Ho HWANG, Yu Kyoung LEE, Mi-kyung KIM
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 9919047
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 20, 2018
    Assignees: SILLAJEN, INC., SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
    Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim